A detailed history of Geode Capital Management, LLC transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 347,567 shares of BOLT stock, worth $260,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares
347,567
Previous 350,164 0.74%
Holding current value
$260,675
Previous $392,000 23.98%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$1.01 - $1.4 $2,622 - $3,635
-2,597 Reduced 0.74%
347,567 $486,000
Q4 2023

Feb 13, 2024

SELL
$0.85 - $1.12 $8,988 - $11,844
-10,575 Reduced 2.93%
350,164 $392,000
Q3 2023

Nov 13, 2023

BUY
$0.98 - $1.46 $8,349 - $12,439
8,520 Added 2.42%
360,739 $375,000
Q2 2023

Aug 11, 2023

BUY
$1.27 - $1.95 $221,268 - $339,742
174,227 Added 97.88%
352,219 $450,000
Q1 2023

May 15, 2023

BUY
$1.29 - $1.66 $30,851 - $39,700
23,916 Added 15.52%
177,992 $247,000
Q4 2022

Feb 13, 2023

BUY
$1.26 - $1.48 $14,934 - $17,542
11,853 Added 8.33%
154,076 $200,000
Q2 2022

Aug 12, 2022

SELL
$1.41 - $2.91 $260,105 - $536,813
-184,472 Reduced 56.47%
142,223 $290,000
Q1 2022

May 13, 2022

SELL
$2.74 - $4.82 $179,297 - $315,406
-65,437 Reduced 16.69%
326,695 $895,000
Q4 2021

Feb 11, 2022

BUY
$4.19 - $13.97 $197,001 - $656,827
47,017 Added 13.62%
392,132 $1.92 Million
Q3 2021

Nov 12, 2021

BUY
$11.15 - $18.6 $1.5 Million - $2.51 Million
134,962 Added 64.22%
345,115 $4.37 Million
Q2 2021

Aug 13, 2021

BUY
$15.4 - $31.46 $4,404 - $8,997
286 Added 0.14%
210,153 $3.25 Million
Q1 2021

May 12, 2021

BUY
$25.86 - $39.93 $5.43 Million - $8.38 Million
209,867 New
209,867 $6.91 Million

Others Institutions Holding BOLT

About Bolt Biotherapeutics, Inc.


  • Ticker BOLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,641,500
  • Market Cap $28.2M
  • Description
  • Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...
More about BOLT
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.